Factors associated with the use of complementary and alternative medicines for prostate cancer by long-term survivors
Article
Article Title | Factors associated with the use of complementary and alternative medicines for prostate cancer by long-term survivors |
---|---|
ERA Journal ID | 39745 |
Article Category | Article |
Authors | Egger, Sam (Author), Hughes, Suzanne (Author), Smith, David P. (Author), Chambers, Suzanne (Author), Kahn, Clare (Author), Moxey, Annette (Author) and O'Connell, Dianne L. (Author) |
Journal Title | PLoS One |
Journal Citation | 13 (3), pp. 1-13 |
Article Number | e0193686 |
Number of Pages | 13 |
Year | 2018 |
Publisher | Public Library of Science (PLoS) |
Place of Publication | United States |
ISSN | 1932-6203 |
Digital Object Identifier (DOI) | https://doi.org/10.1371/journal.pone.0193686 |
Web Address (URL) | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0193686 |
Abstract | Objective To assess whether the use of complementary and alternative medicines therapies (CAMs) for prostate cancer and/or its treatment side effects by long-term survivors is associated with selected socio-demographic, clinical, health-related quality-of-life (HRQOL) and/or psychological factors. Design, setting and participants The Prostate Cancer Care and Outcomes Study (PCOS) is a population-based cohort study of men with prostate cancer who were aged less than 70 years at diagnosis in New South Wales, Australia. Included in these analyses were men who returned a 10-year follow-up questionnaire, which included questions about CAM use. Methods Validated instruments assessed patient’s HRQOL and psychological well-being. Poisson regression with robust variance estimation was used to estimate the adjusted relative risks of current CAM use for prostate cancer according to socio-demographic, clinical, HRQOL and psychological factors. Results 996 of 1634 (61%) living PCOS participants completed the 10-year questionnaire. Of these 996 men, 168 (17%) were using CAMs for prostate cancer and 525 (53%) were using CAMs for any reason (including prostate cancer). Those using CAM for prostate cancer were more likely to be regular or occasional support group participants (vs. no participation RR = 2.02; 95%CI 1.41–2.88), born in another country (vs. Australian born RR = 1.59; 95%CI 1.17–2.16), have received androgen deprivation treatment (ADT) since diagnosis (RR = 1.60; 95%CI 1.12–2.28) or in the past two years (RR = 2.34; 95%CI 1.56–3.52). CAM use was associated with greater fear of recurrence (RR = 1.29; 95%CI 1.12–1.48), cancer-specific distress (RR = 1.15; 95%CI 1.01–1.30), cancer-specific hyperarousal (RR = 1.17; 95%CI 1.04–1.31), cancer locus of control (RR = 1.16; 95%CI 1.01–1.34) and less satisfaction with medical treatments (RR = 0.86; 95%CI 0.76–0.97), but not with intrusive thinking, cognitive avoidance, depression, anxiety or any HRQOL domains. Conclusions In this study, about one in six long term prostate cancer survivors used CAMs for their prostate cancer with use centred around ADT, country of birth, distress, cancer control, fear of recurrence and active help seeking. |
Keywords | Aged; Aged, 80 and over; Australia; Cancer Survivors; Complementary Therapies; Follow-Up Studies; Humans; Longitudinal Studies; Male; Middle Aged; Prostatic Neoplasms; Quality of Life; Regression Analysis; Surveys and Questionnaires |
ANZSRC Field of Research 2020 | 321199. Oncology and carcinogenesis not elsewhere classified |
Byline Affiliations | Cancer Council Australia, Australia |
Institute for Resilient Regions | |
University of Newcastle | |
Institution of Origin | University of Southern Queensland |
https://research.usq.edu.au/item/q76q5/factors-associated-with-the-use-of-complementary-and-alternative-medicines-for-prostate-cancer-by-long-term-survivors
Download files
Published Version
Egger-2018-Factors-associated-with-the-use-of-.pdf | ||
License: CC BY 4.0 | ||
File access level: Anyone |
55
total views30
total downloads2
views this month1
downloads this month